Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 1 results out of 1
Data Insights
P-128 by GangaGen Biotechnologies for Staphylococcus aureus Infections: Likelihood of Approval
P-128 is under clinical development by GangaGen Biotechnologies and currently in Phase II for Staphylococcus aureus Infections. According to GlobalData,...